Sadra Medical Announces Successful Clinical Use of the First Retrievable, Repositionable Transcatheter Aortic Heart Valve

CAMPBELL, Calif.--(BUSINESS WIRE)--Sadra Medical, a privately-held, development stage Silicon Valley firm dedicated to developing innovative new therapies for aortic valve disease, announced today that it has successfully completed the first clinical use of its breakthrough transcatheter aortic valve, the Lotus™ Valve System. The system is designed to enable physicians to replace a diseased aortic valve without opening the chest, instead navigating the valve through the arteries using a catheter-based delivery system.